These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 413732)

  • 21. Effects of trypanocidal drugs on protein biosynthesis in vitro and in vivo by Trypanosoma cruzi.
    Gonzalez NS; Cazzulo JJ
    Biochem Pharmacol; 1989 Sep; 38(17):2873-7. PubMed ID: 2673249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Damage of Trypanosoma cruzi deoxyribonucleic acid by nitroheterocyclic drugs.
    Goijman SG; Frasch AC; Stoppani AO
    Biochem Pharmacol; 1985 May; 34(9):1457-61. PubMed ID: 3888226
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Animal experimental investigation into the activity of nifurtimox against Trypanosoma cruzi.
    Haberkorn A; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1570-82. PubMed ID: 4630483
    [No Abstract]   [Full Text] [Related]  

  • 24. [Reaction of the Trypanosoma cruzi strain to the experimental therapeutical response to Bay 2502 (results of long term treatment)].
    Andrade SG; Figueira RM; Carvalho ML; Gorini DF
    Rev Inst Med Trop Sao Paulo; 1975; 17(6):380-9. PubMed ID: 815983
    [No Abstract]   [Full Text] [Related]  

  • 25. [Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy].
    Silva RC; Santiago CM; Pontes AL; Andrade SG
    Mem Inst Oswaldo Cruz; 1989; 84(1):81-6. PubMed ID: 2108307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TcI, TcII and TcVI Trypanosoma cruzi samples from Chagas disease patients with distinct clinical forms and critical analysis of in vitro and in vivo behavior, response to treatment and infection evolution in murine model.
    Oliveira MT; Branquinho RT; Alessio GD; Mello CGC; Nogueira-de-Paiva NC; Carneiro CM; Toledo MJO; Reis AB; Martins-Filho OAM; Lana M
    Acta Trop; 2017 Mar; 167():108-120. PubMed ID: 27908747
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of glutathione in the susceptibility of Trypanosoma cruzi to drugs.
    Moncada C; Repetto Y; Aldunate J; Letelier ME; Morello A
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1989; 94(1):87-91. PubMed ID: 2576749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Different effects of nifurtimox and benznidazole on the biosynthesis of DNA, RNA and proteins in Trypanosoma cruzi].
    Goijman SG; Frasch AC; Stoppani AO
    Medicina (B Aires); 1984; 44(3):261-70. PubMed ID: 6085847
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug Discovery for Paediatric Chagas Disease.
    Thota S; Morel CM
    Mini Rev Med Chem; 2018; 18(9):776-780. PubMed ID: 26202205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse.
    Morrow DT; Wescott RB; Davis WC
    Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ESR spin trapping studies of free radicals generated from nitrofuran derivative analogues of nifurtimox by electrochemical and Trypanosoma cruzi reduction.
    Olea-Azar C; Rigol C; Mendizabal F; Morello A; Maya JD; Moncada C; Cabrera E; Di Maio R; González M; Cerecetto H
    Free Radic Res; 2003 Sep; 37(9):993-1001. PubMed ID: 14670007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)].
    Cerisola JA; Neves da Silva N; Prata A; Schenone H; Rohwedder R
    Bol Chil Parasitol; 1977; 32(3-4):51-62. PubMed ID: 416834
    [No Abstract]   [Full Text] [Related]  

  • 33. Ultrastructural observations on the activity of nifurtimox on the causative organism of Chagas' disease. I. Trypanosoma cruzi in tissue cultures.
    Voigt WH; Bock M; Gönnert R
    Arzneimittelforschung; 1972 Sep; 22(9):1586-9. PubMed ID: 4567081
    [No Abstract]   [Full Text] [Related]  

  • 34. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.
    Moraes CB; White KL; Braillard S; Perez C; Goo J; Gaspar L; Shackleford DM; Cordeiro-da-Silva A; Thompson RC; Freitas-Junior L; Charman SA; Chatelain E
    Antimicrob Agents Chemother; 2015; 59(6):3645-7. PubMed ID: 25845874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of a novel compound, (e)-1-(4'-bromo-4-biphenylyl)-1-(4-chlorophenyl)-3-dimethylaminoprop-1-ene against Trypanosoma cruzi in mice.
    Barrett PA; Beveridge E; Bull D; Caldwell IC; Islip PJ; Neal RA; Woods NC
    Experientia; 1982 Mar; 38(3):338-9. PubMed ID: 6804255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of nifurtimox on Trypanosoma cruzi in tissue cultures.
    Gönnert R; Bock M
    Arzneimittelforschung; 1972 Sep; 22(9):1582-6. PubMed ID: 4567080
    [No Abstract]   [Full Text] [Related]  

  • 37. [Undesirable effects of benznidazole and nifurtimox].
    Moreno SN; Docampo R; Stoppani AO
    Medicina (B Aires); 1983; 43(3):291-5. PubMed ID: 6323912
    [No Abstract]   [Full Text] [Related]  

  • 38. Current drug therapy and pharmaceutical challenges for Chagas disease.
    Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
    Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of drugs on Trypanosoma cruzi and on its interaction with heart muscle cell "in vitro".
    de Castro SL; de Meirelles Mde N
    Mem Inst Oswaldo Cruz; 1987; 82(2):209-18. PubMed ID: 3333533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.